Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study - Takeaways - MDSpire

Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study

  • By

  • Zhenghua Liu

  • Xinyu Wang

  • Jiayan Gai

  • Chen Wang

  • Xinlu Yi

  • Yufei Liu

  • Tao Zhou

  • June 26, 2026

  • 0 min

Share

  • 1

    The study compared adjuvant trastuzumab plus pertuzumab (HP) with trastuzumab emtansine (T-DM1) in HER2-positive breast cancer patients with residual disease.

  • 2

    A total of 272 patients were analyzed, with 134 remaining after propensity score matching for baseline characteristics.

  • 3

    No statistically significant differences in short-term survival outcomes were found between the HP and T-DM1 groups after a median follow-up of 37.7 months.

  • 4

    Grade 3 or higher adverse events were more frequent in the T-DM1 group, particularly thrombocytopenia, with higher treatment interruption rates.

  • 5

    HP demonstrated a more favorable safety and tolerability profile compared to T-DM1 in patients with HER2-positive breast cancer after neoadjuvant therapy.

Original Source(s)

Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study

  • by Zhenghua Liu, Xinyu Wang, Jiayan Gai, Chen Wang, Xinlu Yi, Yufei Liu, Tao Zhou

  • June 26, 2026

Related Content

ESMO Breast Cancer 2026 Highlights Panel Discussion

Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Erica L. Mayer, MD, MPH; Nancy Lin, MD; and Ana C. Garrido-Castro, MD discuss important breast cancer research presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min
Trends, survival and regional control of sentinel lymph node biopsy versus axillary dissection in cN0 breast cancer: a multicenter cohort in China

Effectiveness of a Home-Based and Group-Based Tele-Exercise Program for Breast Cancer Survivors: Pilot Randomized Controlled Trial